AAPS Blog Committee

Committee Charge

The charge of the AAPS Blog Committee (ABC) is to help solicit and secure topical and timely content for the AAPS blog.


Abimbola Farinde | PPDM Section Representative

Abimbola Farinde

Abimbola Farinde, Ph.D., is a clinical pharmacist specialist with specializations in psychopharmacology and geriatrics. Farinde is an adjunct pharmacology instructor and an associate editor of several healthcare and scientific journals.



Harsh Sancheti | CPTR Section Representative

Harsh SanchetiHarsh Sancheti is near completion of his doctoral degree in Pharmacology from the University of Southern California. His primary research has focused on Alzheimer’s disease. Currently, he is also working as an “Innovation Intern” at the USC Stevens Center for Innovation. He has completed a bachelor’s degree in Pharmacy from Pune University followed by a master’s degree in Pharmaceutical Science,s and a second master’s degree in Regulatory Sciences from the USC School of Pharmacy.


Kaushal Dave | FDD Section representative

Kaushal DaveKaushal Dave is a Ph.D. student at the Department of Pharmaceutical Sciences, South Dakota State University and completed his Master of Pharmacy at Rajeev Gandhi University of Health Sciences, India. He has two years of experience in parenteral formulations, and his current research focuses on localized delivery of therapeutics against breast cancer. Besides research, Dave has been involved in several scientific, community, and sports activities at South Dakota State University, including being an avid cricket player.


Maria Posada | PPB Section representative

Maria PosadaMaria M. Posada, Ph.D., is a post-doctoral scientist in the Drug Disposition department at Eli Lilly and Company. Maria’s research focuses on membrane transporter proteins and their role on the intestinal absorption and the renal elimination of drugs. She uses in vitro in vivo extrapolation (IVIVE) techniques and mechanistic models to predict drug exposure, tissue concentrations, and transporter-mediated drug interactions in humans.


Megan Cooley | APQ Section Representative

Megan CooleyMegan Cooley, Ph.D., is a postdoctoral fellow at the University of Kansas Medical Center, Department of Cancer Biology. Her research group (Dr. Jeremy Chien’s Lab) is focused on developing assays to improve the diagnosis of early stage ovarian cancer and to enhance treatment options of advanced stage ovarian cancer. Additionally, her research group is also interested in understanding the effects of the tumor microenvironment on acquired chemoresistance and metastasis.


Mehran Yazdanian | DDDI Section representative

Mehran YazdanianMehran Yazdanian, Ph.D., is the Director of Analytical Development at Teva Pharmaceuticals Inc. He received his bachelor’s degree in biochemistry and master’s and doctoral degrees in pharmaceutics from the University of Wisconsin-Madison. His current responsibilities are concentrated on directing analytical development activities from early drug discovery support and preformulation to analytical method development and validation for clinical programs.


Prasanna Kolluru | RS Section Representative

Prasanna KolluruPrasanna Kolluru is a Ph.D. candidate at Mercer University under Martin D’Souza, Ph.D. Kolluru works on development of theragnostic nanoparticles for tumor targeted drug delivery. In her free time, Kolluru enjoys penning down articles for newspaper columns.



Prathap Shastri | BIOTEC Section Representative

Prathap ShastriPrathap Shastri works for the ADME/DMPK group at WIL Research Laboratories in Ashland, Ohio. Prior to joining WIL research, he worked at Seventh Wave Laboratories working as a principal investigator for the PDM group. He received his doctorate in pharmaceutical sciences from Mercer University, Atlanta where he worked on formulation and development of protein and polysaccharide based vaccines.


Rahul Haware | MSE Section Representative

Rahul HawareRahul Haware, Ph.D., is assistant professor of pharmaceutical sciences at Campbell University. His main research focus is on the emerging field of ‘Pharmaceutical Material Science’ to investigate the impact of the physico-mechanical properties of crystalline and amorphous materials on their final dosage form design.



Robert Bell | Committee Chair

Robert BellRobert G. Bell, Ph.D., is President/Owner of Drug and Biotechnology Development LLC, a consultancy to the pharmaceutical industry and academia for biological, drug and device development. Bell received his bachelor’s degree in Chemistry, master’s degree in Food Science and Human Nutrition and his doctoral degree in Pharmaceutics from the University of Florida. His employment history includes Carter-Wallace, Inc., AL Pharma, UDL Laboratories, Inc., Somerset Pharmaceuticals, Inc. and Barr Laboratories, Inc.


Russ Weiner | EC Liason

Russell WeinerRuss Weiner, Ph.D., is currently Executive Director and Head of Molecular Biomarkers and Diagnostics at Merck. In this role he is responsible for delivering on global biomarker and companion diagnostic strategies for all of Merck’s therapeutic areas. After receiving his doctoral degree in Biochemistry from Albany Medical College, Russ then spent the next 18 years at BMS where he was responsible for discovery and regulated bioanalysis (GLP and clinical) in support of PK, immunogencity and biomarker assay development, validation and sample analysis. Russ has extensive experience in clinical project leadership, clinical trial conduct, development of pharmaceutical and biologics therapeutics and is well versed in using biomarkers for early decision making. Russ is an active member of the American Association of Pharmaceutical Scientists (AAPS) where he currently serves as a member of the AAPS Executive Board. Russ is well known for his passion for student mentorship and travels to graduate schools as part of the AAPS Visiting Scientist effort where he provides training on soft skills and career development.


2 thoughts on “AAPS Blog Committee”

  1. The following comment is regards to 2015 Annual Meeting Themes: The Challenges of QbD post. I have also posted an addendum to the post. I would like my comment to published and posted as is. Thanks.

    I am totally shocked at the statement “pharmaceutical industry’s antiquated drug development model”. Every part of pharma and that includes drug discovery, process development, commercialization, supply chain and manufacturing practices are antiquated. They are about sixty years behind times. They can and should learn from their older cousins specialty/fine chemicals and petrochemicals what is possible and feasible.

    Manufacturing of APIs is inefficient and formulation practices really antiquated even when the equipment and practices have been around for the last 60+ years.

    If someone believes that regulatory bodies can bring modernity to pharma industry then it would be saying that Sun will rise in the west. Regulatory bodies cannot do anything. Pharma companies have to take the lead. Since they have not moved new buzz words PAT/QBD and many three letter acronyms (TLAs) have been introduced. But all these are worthless unless pharma companies take change to innovate.

    It is like we control and and manage our destiny same happens with any other industry. Pharma has been shielded because patients will pay anything and that includes the highest price to live.

    Pharma has not had the need to innovate as it can make desired profits with their inefficient practices.

    I apologize for being extremely critical but making statements that regulatory bodies are suggesting change is putting cart before the horse.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s